The group also showed that treating SKBR3 and HCC1954 breast cancer cells with lapatinib (inhibitor of EGFR/ErbB1 and ErbB2) led to a decrease in PHLDA1 as assessed by immunoblotting. The gene discussed is ERBB2; the disease is breast carcinoma.